This site is intended for healthcare professionals

Dermavant to present new data from phase III PSOARING program for tapinarof cream at the 2022 Winter Clinical Dermatology Conference.

Read time: 1 mins
Published:9th Jan 2022
Dermavant Sciences announced that new patient satisfaction data from PSOARING 3, the long-term extension study of tapinarof cream for the treatment of plaque psoriasis in adults, will be presented at the 2022 Winter Clinical Dermatology Conference, to be held Jan.

14-19 in Koloa, Hawaii. This poster will report data from a Patient Satisfaction Questionnaire, administered at study completion, designed to assess patient satisfaction with tapinarof efficacy, formulation elegance, application ease, impact on daily life and preference for tapinarof versus prior psoriasis therapies.

Dermavant’s pivotal Phase III clinical program for tapinarof in adult plaque psoriasis consists of PSOARING 1 (NCT03956355) and PSOARING 2 (NCT03983980), as well as PSOARING 3 (NCT04053387), a long-term extension study. PSOARING 1 and PSOARING 2, which collectively enrolled 1,025 patients, were two identically designed, multi-center, randomized, vehicle-controlled, double-blind, parallel group studies conducted in North America that evaluated the safety and efficacy of tapinarof cream, 1% dosed once daily (QD) for 12 weeks versus vehicle QD in adult patients aged 18-75 years diagnosed with plaque psoriasis. The primary endpoint of both studies was the proportion of patients who achieved a PGA score of clear (0) or almost clear (1) with a minimum 2-grade improvement from baseline at Week 12.

PSOARING 3 was a long-term, open-label, extension study to evaluate the safety and efficacy of tapinarof cream, 1% for the treatment of plaque psoriasis in adults. Patients in the study had previously completed treatment with tapinarof or vehicle in either the PSOARING 1 or PSOARING 2 Phase III pivotal efficacy and safety studies. PSOARING 3 consisted of up to 40 weeks of tapinarof cream, 1%, and a 4-week safety follow-up period. As such, patients who received drug during PSOARING 1 and PSOARING 2 completed PSOARING 3, having received treatment with tapinarof cream for up to 52 weeks. Greater than 90% of eligible patients who completed PSOARING 1 and PSOARING 2 enrolled in PSOARING 3. Dermavant released interim analysis results from PSOARING 3 in February 2021 and the study completed on April 5, 2021.

Condition: Psoriasis
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.